{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-076911","form_type":"8-K","ticker":"BOLD","cik":"0001782303","company_name":"Boundless Bio, Inc.","filed_at":"2025-05-23T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.693928+00:00","generated_at":"2026-05-20T14:55:34.359839+00:00","sec_items":["2.05","8.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Boundless Bio restructures pipeline, cuts workforce 33%, discontinues BBI-355 monotherapy","bullets":["Workforce reduction of ~1/3; expects $1.2M one-time costs, substantially completed in Q2 2025.","Discontinues current POTENTIATE trial arms for BBI-355 due to narrow therapeutic index and poor tolerability.","Plans to develop BBI-355/BBI-825 combination; initial clinical data expected within extended cash runway.","Selects BBI-940 as Kinesin program candidate; IND submission expected first half 2026.","Cash, equivalents & investments $138.3M as of March 31, 2025; operating runway extended into first half 2028."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-076911","json":"https://secwatch.observer/filing/0000950170-25-076911.json","markdown":"https://secwatch.observer/filing/0000950170-25-076911.md","text":"https://secwatch.observer/filing/0000950170-25-076911.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1782303/000095017025076911/0000950170-25-076911-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1782303/000095017025076911/bold-20250523.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-20T14:55:34.359839+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"08e42f6265d58f2c19480e384f999d5c668de951","claim":"Boundless Bio, Inc. announced a restructuring with charges of approximately $1.2 million (approximately one-third of the Company’s workforce).","evidence_excerpt":"On May 23, 2025, Boundless Bio, Inc. (the Company), in connection with the portfolio prioritization described below, announced a workforce reduction of approximately one-third of the Company’s workforce. The Company expects to incur one-time costs of approximately $1.2 million in connection with the workforce reduction primarily related to one-time termination benefits (some of which are contractual), including severance and healthcare related benefits.","evidence_source":"SEC 8-K Item 2.05/2.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1782303/000095017025076911/0000950170-25-076911-index.htm","confidence":0.9,"family_label":"Restructurings & Charges","details":[{"label":"Type","value":"restructuring"},{"label":"Charge","value":"approximately $1.2 million"},{"label":"Headcount","value":"approximately one-third of the Company’s workforce"}],"fact_type":"restructuring_charge"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}